The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients

Journal of Surgical Oncology

Volumn 106, Issue 4, 2012, Pages 393-398

  Parker, Catherine C ^a   Kim, Roger H ^a,b   Li, Benjamin D L ^a,b   Chu, Quyen D ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

chemokine receptor CXCR4; node positive breast cancer; prognostic marker

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NODE POSITIVE BREAST CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CXCR4;

EID: 84865128197     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23113     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, et al.: Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Müller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
3. Silverstein MJ, Skinner KA, Lomis TJ,: Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25: 767-772. (Pubitemid 32531925)
4. Chua B, Ung O, Taylor R, et al.: Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001; 71: 723-728. (Pubitemid 34014708)
5. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN,: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
6. Proudfoot A,: Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115. (Pubitemid 37323234)
7. Ben-Baruch A,: The multifaceted roles of chemokines in malignancy. Cancer Metast Rev 2006; 25: 357-371. (Pubitemid 44922355)
8. Ottaniano A, Franco R, Aiello Talamanca A, et al.: Overexpression of Both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stages II-III colorectal cancer patients. Clin Cancer Res 2006; 12: 2795-2803.
9. Murakami T, Maki W, Cardones AR, et al.: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62: 7328-7334. (Pubitemid 36025256)
10. Kato M, Kitayama J, Kazama S, et al.: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: 144-150.
11. Kang H, Watkins G, Douglas-Jones A, et al.: The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005; 14: 360-367. (Pubitemid 41510192)
12. Woodhouse EC, Chuaqui RF, Liotta LA,: General mechanisms of metastasis. Cancer 1997; 80: 1529-1537. (Pubitemid 27444024)
13. Lee BC, Lee TH, Avraham S, et al.: Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2004; 6: 327-338. (Pubitemid 39025295)
14. Liang Z, Yoon Y, Votaw J, et al.: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65: 967-971. (Pubitemid 40216458)
15. Lapteva N, Yang AG, Sanders DE, et al.: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005; 12: 84-89. (Pubitemid 39665246)
16. Smith MC, Luker KE, Garbow JR, et al.: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612. (Pubitemid 39552073)
17. Knechtel G, Hofmann G, Gerger A, et al.: Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 2010; 136: 1813-1819.
18. Loussouarn D, Campion L, Leclair F, et al.: Validation of UBE2C protein as a Prognostic marker in node-positive breast cancer. Br J Cancer 2009; 101: 166-173.
19. Danko ME, Bennett KM, Zhai J, et al.: Improved staging in node-positive breast cancer patients using lymph node ratio: Results in 1,788 patients with long-term follow-up. J Am Coll Surg 2010; 210: 797-805.
20. Wang SL, Li YX, Song YW, et al.: Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys 2011; 80: 1095-1101.
21. Dumontet C, Krajewska M, Treilleux I, et al.: BCIRG 001 molecular analysis: Prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010; 16: 3988-3997.
22. Campone M, Campion L, Roché H, et al.: Prediction of metastatic relapse in node-positive breast cancer: Establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 2008; 109: 491-501. (Pubitemid 351692060)
23. Mizell J, Panu L, Johnson L, et al.: Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: A validation study. Ann Surg Oncol 2009; 16: 2711-2716.
24. Chu QD, Panu L, Holm N, et al.: High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 2010; 159: 689-695.
25. Stead L, Lash T, Sobeieraj J, et al.: Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
26. Jones B, Kasl S, Howe C, et al.: African American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004; 101: 1293-1301. (Pubitemid 39180384)
27. Elledge RM, Clark GM, Chamness GC, et al.: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994; 86: 705-712. (Pubitemid 24138977)
28. McShane LM, Altman DG, et al.: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229-235. (Pubitemid 44631925)